RNASET2 and neoplasm: In the case of RNASET2, whose catalytic mutants inhibit tumorigenesis by recruiting competent immune cells to tumor sites, plasma membrane trafficking (evidenced in [29]) and glycosylation of the T2 protein [36] might enable immune surveillance at the cell surface.